Lifevantage vs Ligand Pharmaceuticals
LFVN and LGND side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How LFVN and LGND compare
Ligand Pharmaceuticals is the larger company, worth 99 times as much as Lifevantage ($6.2B against $62.3M).
On earnings, Lifevantage is cheaper: it trades at 23.7× trailing earnings, against 135× for Ligand Pharmaceuticals.
Ligand Pharmaceuticals grew revenue faster over the last twelve months (1.0% versus −24.8% for Lifevantage).
Ligand Pharmaceuticals keeps more of each dollar of sales as profit, with a net margin of 20.3% compared with 1.6% at Lifevantage.
Lifevantage pays a dividend yielding 3.8%; Ligand Pharmaceuticals does not pay one.
Lifevantage scores higher on the StockData Score (16 against 6 for Ligand Pharmaceuticals), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | LFVN | LGND |
|---|---|---|
| Size and price | ||
| Market cap | $62.3M | $6.2B |
| Share price | $4.97 | $308.79 |
| Change, 1 year | −25.2% | 50.2% |
| Change, 5 years | −32.7% | 90.7% |
| Beta (5Y) | 0.38 | 1.30 |
| Employees | 223 | 47 |
| StockData Score | ||
| Total score | 16 (better) | 6 |
| Valuation score | 4 (better) | 0 |
| Growth score | 1 | 1 |
| Performance score | 3 | 3 |
| Health score | 5 (better) | 2 |
| Dividend score | 3 (better) | 0 |
| Valuation | ||
| P/E | 23.7× (better) | 135× |
| P/S | 0.4× (better) | 24.3× |
| P/B | 1.9× (better) | 6.4× |
| EV/EBITDA | 7.4× (better) | 113× |
| P/FCF | 7.2× (better) | 68.2× |
| PEG | 0.91 | – |
| FCF yield | 14.0% (better) | 1.5% |
| Fair value | $6.48 | $55.48 |
| Margin of safety | 23.3% (better) | −457% |
| Growth | ||
| Revenue growth (TTM) | −24.8% | 1.0% (better) |
| Revenue growth, 5Y average | −3.7% | 10.4% (better) |
| Net income growth (TTM) | −73.1% | 5.9% (better) |
| EPS growth (TTM) | −72.7% | 18.7% (better) |
| EPS growth, 5Y average | −15.0% | – |
| Profitability | ||
| Gross margin | 76.5% | – |
| Operating margin | 2.1% | 10.1% (better) |
| Net margin | 1.6% | 20.3% (better) |
| FCF margin | 5.1% | 35.7% (better) |
| Return on equity | 8.2% (better) | 5.4% |
| Return on invested capital | 14.0% (better) | 2.6% |
| Financial health | ||
| Debt / equity | 0.00 | 1.17 (better) |
| Net debt / EBITDA | – | 11.26 |
| Interest coverage | – | 3.1× |
| Current ratio | 1.91 (better) | 1.22 |
| Altman Z-score | 2.42 | 3.46 (better) |
| Piotroski F-score | 6 | 6 |
| Dividends and buybacks | ||
| Dividend yield | 3.8% | – |
| Payout ratio | 88.2% | – |
| Years of dividend growth | 1 | – |
| Buyback yield | 2.4% | – |
| Shareholder yield | 6.2% (better) | 0.00% |
| Ownership | ||
| Held by institutions | 47.2% | 113% |
| Held by insiders | 27.8% | 2.6% |
| Insider net buying, 12 months | $54.8K (better) | −$35.7M |
| Short interest, % of float | 10.0% | – |
Go deeper
- LFVN stock overview
- LFVN income statement
- LFVN valuation and score
- LGND stock overview
- LGND income statement
- LGND valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.